Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
2 Adipocytokine signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
3 Adipocytokine signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
4 African trypanosomiasis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
5 African trypanosomiasis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
6 African trypanosomiasis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
7 African trypanosomiasis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
8 African trypanosomiasis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
14 Alcoholic liver disease 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
15 Alcoholic liver disease 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
16 Alcoholic liver disease 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
17 Alcoholic liver disease 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
18 Alcoholic liver disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
19 Alcoholic liver disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
20 Alcoholic liver disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
21 Alcoholic liver disease 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
22 Allograft rejection 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
23 Allograft rejection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
24 Allograft rejection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
25 Alzheimer disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
26 Alzheimer disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
27 Alzheimer disease 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
28 Alzheimer disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
29 Alzheimer disease 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
30 Amoebiasis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
31 Amoebiasis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
32 Amoebiasis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
33 Amoebiasis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
34 Amoebiasis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
35 Amphetamine addiction 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
36 Amyotrophic lateral sclerosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
37 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
38 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
39 Antigen processing and presentation 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
40 Antigen processing and presentation 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
41 Apoptosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
42 Apoptosis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
43 Asthma 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
44 Asthma 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
45 Axon guidance 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
46 B cell receptor signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
47 C-type lectin receptor signaling pathway 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
48 C-type lectin receptor signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
49 C-type lectin receptor signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
50 C-type lectin receptor signaling pathway 💬
1件: IL23A 💬 Guselkumab 💬 Guselkumab 7件: 37, 41, 51, 96, 97, 161, 269 💬
51 C-type lectin receptor signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
52 C-type lectin receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
53 C-type lectin receptor signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
54 Calcium signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
55 Cellular senescence 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
56 cGMP-PKG signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
57 Chagas disease 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
58 Chagas disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
59 Chagas disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
60 Chagas disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
61 Chagas disease 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
62 Chemical carcinogenesis - receptor activation 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
63 Chemokine signaling pathway 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
64 Cholinergic synapse 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
65 Complement and coagulation cascades 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
66 Coronavirus disease - COVID-19 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
67 Coronavirus disease - COVID-19 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
68 Coronavirus disease - COVID-19 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
69 Coronavirus disease - COVID-19 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
70 Coronavirus disease - COVID-19 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
71 Coronavirus disease - COVID-19 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
72 Coronavirus disease - COVID-19 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
73 Coronavirus disease - COVID-19 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
74 Cytokine-cytokine receptor interaction 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
75 Cytokine-cytokine receptor interaction 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
76 Cytokine-cytokine receptor interaction 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
77 Cytokine-cytokine receptor interaction 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
78 Cytokine-cytokine receptor interaction 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
79 Cytokine-cytokine receptor interaction 💬
1件: IL1RL2 💬 Spesolimab 💬 Spesolimab 5件: 37, 96, 97, 160, 269 💬
80 Cytokine-cytokine receptor interaction 💬
1件: IL23A 💬 Guselkumab 💬 Guselkumab 7件: 37, 41, 51, 96, 97, 161, 269 💬
81 Cytokine-cytokine receptor interaction 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
82 Cytokine-cytokine receptor interaction 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
83 Cytosolic DNA-sensing pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
84 Cytosolic DNA-sensing pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
85 Dilated cardiomyopathy 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
86 Dilated cardiomyopathy 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
87 Dopaminergic synapse 💬
3件: PPP3C, PPP3C, PPP3C 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
88 Efferocytosis 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
89 Epstein-Barr virus infection 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
90 Epstein-Barr virus infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
91 Epstein-Barr virus infection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
92 Epstein-Barr virus infection 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
93 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
94 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
95 Fluid shear stress and atherosclerosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
96 Fluid shear stress and atherosclerosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
97 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
98 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
99 Glucagon signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
100 Glutamatergic synapse 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
101 Graft-versus-host disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
102 Graft-versus-host disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
103 Graft-versus-host disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
104 Graft-versus-host disease 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
105 Growth hormone synthesis, secretion and action 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
106 Hematopoietic cell lineage 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
107 Hematopoietic cell lineage 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
108 Hematopoietic cell lineage 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
109 Hematopoietic cell lineage 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
110 Hepatitis B 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
111 Hepatitis B 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
112 Hepatitis B 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
113 Hepatitis B 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
114 Hepatitis C 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
115 Hepatitis C 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
116 Hepatitis C 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
117 Hepatitis C 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
118 Herpes simplex virus 1 infection 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
119 Herpes simplex virus 1 infection 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
120 Herpes simplex virus 1 infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
121 Herpes simplex virus 1 infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
122 Herpes simplex virus 1 infection 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
123 Herpes simplex virus 1 infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
124 Herpes simplex virus 1 infection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
125 Herpes simplex virus 1 infection 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
126 Hormone signaling 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
127 Human cytomegalovirus infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
128 Human cytomegalovirus infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
129 Human cytomegalovirus infection 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
130 Human cytomegalovirus infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
131 Human cytomegalovirus infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
132 Human cytomegalovirus infection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
133 Human immunodeficiency virus 1 infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
134 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
135 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
136 Human papillomavirus infection 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
137 Human papillomavirus infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
138 Human papillomavirus infection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
139 Human papillomavirus infection 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
140 Human T-cell leukemia virus 1 infection 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
141 Human T-cell leukemia virus 1 infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
142 Human T-cell leukemia virus 1 infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
143 Human T-cell leukemia virus 1 infection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
144 Hypertrophic cardiomyopathy 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
145 Hypertrophic cardiomyopathy 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
146 IL-17 signaling pathway 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
147 IL-17 signaling pathway 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
148 IL-17 signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
149 IL-17 signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
150 IL-17 signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
151 IL-17 signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
152 Inflammatory bowel disease 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
153 Inflammatory bowel disease 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
154 Inflammatory bowel disease 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
155 Inflammatory bowel disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
156 Inflammatory bowel disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
157 Inflammatory bowel disease 💬
1件: IL23A 💬 Guselkumab 💬 Guselkumab 7件: 37, 41, 51, 96, 97, 161, 269 💬
158 Inflammatory bowel disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
159 Inflammatory bowel disease 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
160 Inflammatory mediator regulation of TRP channels 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
161 Inflammatory mediator regulation of TRP channels 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
162 Influenza A 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
163 Influenza A 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
164 Influenza A 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
165 Influenza A 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
166 Influenza A 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
167 Influenza A 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
168 Influenza A 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
169 Insulin resistance 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
170 Insulin resistance 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
171 JAK-STAT signaling pathway 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
172 JAK-STAT signaling pathway 💬
1件: IL23A 💬 Guselkumab 💬 Guselkumab 7件: 37, 41, 51, 96, 97, 161, 269 💬
173 JAK-STAT signaling pathway 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
174 JAK-STAT signaling pathway 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
175 Kaposi sarcoma-associated herpesvirus infection 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
176 Kaposi sarcoma-associated herpesvirus infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
177 Kaposi sarcoma-associated herpesvirus infection 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
178 Legionellosis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
179 Legionellosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
180 Legionellosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
181 Legionellosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
182 Legionellosis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
183 Leishmaniasis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
184 Leishmaniasis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
185 Leishmaniasis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
186 Leishmaniasis 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
187 Leishmaniasis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
188 Leishmaniasis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
189 Lipid and atherosclerosis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
190 Lipid and atherosclerosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
191 Lipid and atherosclerosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
192 Lipid and atherosclerosis 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
193 Lipid and atherosclerosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
194 Lipid and atherosclerosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
195 Lipid and atherosclerosis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
196 Long-term potentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
197 Malaria 💬
1件: IL12A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
198 Malaria 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
199 Malaria 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
200 Malaria 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
201 Malaria 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
202 MAPK signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
203 MAPK signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
204 MAPK signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
205 MAPK signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
206 MAPK signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
207 Measles 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
208 Measles 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
209 Measles 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
210 Measles 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
211 Measles 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
212 mTOR signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
213 mTOR signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
214 Natural killer cell mediated cytotoxicity 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
215 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
216 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
217 Necroptosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
218 Necroptosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
219 Necroptosis 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
220 Necroptosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
221 Necroptosis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
222 Necroptosis 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
223 Neuroactive ligand-receptor interaction 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
224 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Prednisolone 💬 Prednisolone 41件:  3 , 11, 13, 14, 18, 25, 26, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 54, 56, 60, 61, 63, 64, 66, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 251, 269, 271, 296, 299, 300 💬
225 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Prednisone 💬 Prednisone 54件:  2 , 11, 13, 14, 18, 19, 26, 28, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 60, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 90, 93, 95, 96, 97, 113, 145, 162, 164, 205, 222, 224, 228, 251, 269, 283, 285, 288, 299, 300, 303, 307, 331 💬
226 Neutrophil extracellular trap formation 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
227 NF-kappa B signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
228 NF-kappa B signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
229 NF-kappa B signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
230 NF-kappa B signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
231 NOD-like receptor signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
232 NOD-like receptor signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
233 NOD-like receptor signaling pathway 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
234 NOD-like receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
235 NOD-like receptor signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
236 NOD-like receptor signaling pathway 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
237 Non-alcoholic fatty liver disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
238 Non-alcoholic fatty liver disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
239 Non-alcoholic fatty liver disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
240 Non-alcoholic fatty liver disease 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
241 Oocyte meiosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
242 Osteoclast differentiation 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
243 Osteoclast differentiation 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
244 Osteoclast differentiation 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
245 Osteoclast differentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
246 Osteoclast differentiation 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
247 Osteoclast differentiation 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
248 Osteoclast differentiation 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
249 Oxytocin signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
250 Pancreatic cancer 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
251 Pathogenic Escherichia coli infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
252 Pathogenic Escherichia coli infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
253 Pathogenic Escherichia coli infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
254 Pathogenic Escherichia coli infection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
255 Pathways in cancer 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
256 Pathways in cancer 💬
1件: IL23A 💬 Guselkumab 💬 Guselkumab 7件: 37, 41, 51, 96, 97, 161, 269 💬
257 Pathways in cancer 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
258 Pathways of neurodegeneration - multiple diseases 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
259 Pathways of neurodegeneration - multiple diseases 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
260 Pathways of neurodegeneration - multiple diseases 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
261 Pathways of neurodegeneration - multiple diseases 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
262 Pathways of neurodegeneration - multiple diseases 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
263 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
264 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
265 Pertussis 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
266 Pertussis 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
267 Pertussis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
268 Pertussis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
269 Pertussis 💬
1件: IL23A 💬 Guselkumab 💬 Guselkumab 7件: 37, 41, 51, 96, 97, 161, 269 💬
270 Pertussis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
271 Pertussis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
272 PI3K-Akt signaling pathway 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
273 Prion disease 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
274 Prion disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
275 Prion disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
276 Prion disease 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
277 Prion disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
278 Prion disease 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
279 Prolactin signaling pathway 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
280 Proteoglycans in cancer 💬
1件: IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
281 Proteoglycans in cancer 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
282 Proteoglycans in cancer 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
283 Regulation of actin cytoskeleton 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
284 Renin secretion 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
285 Rheumatoid arthritis 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
286 Rheumatoid arthritis 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
287 Rheumatoid arthritis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
288 Rheumatoid arthritis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
289 Rheumatoid arthritis 💬
1件: IL23A 💬 Guselkumab 💬 Guselkumab 7件: 37, 41, 51, 96, 97, 161, 269 💬
290 Rheumatoid arthritis 💬
1件: IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
291 Rheumatoid arthritis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
292 Rheumatoid arthritis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
293 RIG-I-like receptor signaling pathway 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
294 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
295 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
296 Salmonella infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
297 Salmonella infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
298 Salmonella infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
299 Salmonella infection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
300 Shigellosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
301 Shigellosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
302 Shigellosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
303 Shigellosis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
304 Signaling pathways regulating pluripotency of stem cells 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
305 Sphingolipid signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
306 Sphingolipid signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
307 Staphylococcus aureus infection 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
308 Systemic lupus erythematosus 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
309 Systemic lupus erythematosus 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
310 Systemic lupus erythematosus 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
311 T cell receptor signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
312 T cell receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
313 T cell receptor signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
314 TGF-beta signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
315 TGF-beta signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
316 Th1 and Th2 cell differentiation 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
317 Th1 and Th2 cell differentiation 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
318 Th1 and Th2 cell differentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
319 Th1 and Th2 cell differentiation 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
320 Th17 cell differentiation 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
321 Th17 cell differentiation 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
322 Th17 cell differentiation 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
323 Th17 cell differentiation 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
324 Th17 cell differentiation 💬
1件: IL23A 💬 Guselkumab 💬 Guselkumab 7件: 37, 41, 51, 96, 97, 161, 269 💬
325 Th17 cell differentiation 💬
1件: IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
326 Th17 cell differentiation 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
327 Th17 cell differentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
328 Th17 cell differentiation 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
329 TNF signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
330 TNF signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
331 TNF signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
332 TNF signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
333 Toll-like receptor signaling pathway 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
334 Toll-like receptor signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
335 Toll-like receptor signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
336 Toll-like receptor signaling pathway 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
337 Toll-like receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
338 Toll-like receptor signaling pathway 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
339 Toll-like receptor signaling pathway 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
340 Toxoplasmosis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
341 Toxoplasmosis 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
342 Toxoplasmosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
343 Toxoplasmosis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
344 Toxoplasmosis 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
345 Tuberculosis 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
346 Tuberculosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
347 Tuberculosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
348 Tuberculosis 💬
1件: IL23A 💬 Guselkumab 💬 Guselkumab 7件: 37, 41, 51, 96, 97, 161, 269 💬
349 Tuberculosis 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
350 Tuberculosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
351 Tuberculosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
352 Tuberculosis 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
353 Type I diabetes mellitus 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
354 Type I diabetes mellitus 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
355 Type I diabetes mellitus 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
356 Type I diabetes mellitus 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
357 Type I diabetes mellitus 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
358 Type II diabetes mellitus 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
359 Type II diabetes mellitus 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
360 VEGF signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
361 Viral carcinogenesis 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
362 Viral protein interaction with cytokine and cytokine receptor 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
363 Viral protein interaction with cytokine and cytokine receptor 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬
364 Wnt signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
365 Yersinia infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
366 Yersinia infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
367 Yersinia infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
368 Yersinia infection 💬
1件: TNF 💬 Infliximab 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 164, 269, 270, 271 💬